$38.02
Pfizer Inc is a multinational pharmaceutical corporation that produces and develops a wide range of innovative health products.
Revenue is down for the last 2 quarters, 24.29B → 18.28B (in $), with an average decrease of 24.7% per quarter
Netprofit is up for the last 2 quarters, 4.99B → 5.54B (in $), with an average increase of 9.9% per quarter
In the last 1 year, Pfizer Inc. has experienced a drawdown of -27.8%, however Procter & Gamble Co. resisted the overall trend and outperformed by 25.6%
In the last 3 years, Procter & Gamble Co. has given 21.9% return, outperforming this stock by 16.8%
0.83%
Downside
Day's Volatility :1.29%
Upside
0.46%
4.87%
Downside
52 Weeks Volatility :32.83%
Upside
29.4%
Period | Pfizer Inc. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -6.4% | 0.7% | 6.0% |
6 Months | -25.32% | -7.9% | 3.7% |
1 Year | -27.83% | -2.0% | 1.1% |
3 Years | 5.14% | 25.4% | 37.0% |
Market Capitalization | 214.6B |
Book Value | $17.89 |
Dividend Share | 1.61 |
Dividend Yield | 4.43% |
Earnings Per Share (EPS) | 5.07 |
PE Ratio | 7.5 |
PEG Ratio | 1.17 |
Wall Street Target Price | 47.06 |
Profit Margin | 31.25% |
Operating Margin TTM | 37.87% |
Return On Assets TTM | 11.59% |
Return On Equity TTM | 31.62% |
Revenue TTM | 93.0B |
Revenue Per Share TTM | 16.56 |
Quarterly Revenue Growth YOY | -28.799999999999997% |
Gross Profit TTM | 66.2B |
EBITDA | 40.5B |
Diluted Eps TTM | 5.07 |
Quarterly Earnings Growth YOY | -0.29 |
EPS Estimate Current Year | 3.35 |
EPS Estimate Next Year | 3.5 |
EPS Estimate Current Quarter | 0.98 |
EPS Estimate Next Quarter | 0.7 |
What analysts predicted
Upside of 23.78%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 52.5B | ↓ 0.53% |
Net Income | 21.3B | ↑ 195.33% |
Net Profit Margin | 40.55% | ↑ 26.89% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 53.6B | ↑ 2.1% |
Net Income | 11.2B | ↓ 47.66% |
Net Profit Margin | 20.79% | ↓ 19.76% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 51.8B | ↓ 3.54% |
Net Income | 16.3B | ↑ 45.91% |
Net Profit Margin | 31.45% | ↑ 10.66% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 41.9B | ↓ 19.02% |
Net Income | 9.6B | ↓ 40.91% |
Net Profit Margin | 22.95% | ↓ 8.5% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 81.3B | ↑ 93.97% |
Net Income | 22.0B | ↑ 128.57% |
Net Profit Margin | 27.04% | ↑ 4.09% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 100.3B | ↑ 23.43% |
Net Income | 31.4B | ↑ 42.74% |
Net Profit Margin | 31.27% | ↑ 4.23% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 23.6B | ↓ 1.91% |
Net Income | 3.4B | ↓ 58.35% |
Net Profit Margin | 14.36% | ↓ 19.45% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 25.7B | ↑ 8.57% |
Net Income | 7.9B | ↑ 131.77% |
Net Profit Margin | 30.65% | ↑ 16.29% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 27.7B | ↑ 8.11% |
Net Income | 9.9B | ↑ 25.97% |
Net Profit Margin | 35.71% | ↑ 5.06% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 22.6B | ↓ 18.4% |
Net Income | 8.6B | ↓ 13.1% |
Net Profit Margin | 38.02% | ↑ 2.31% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 24.3B | ↑ 7.3% |
Net Income | 5.0B | ↓ 41.97% |
Net Profit Margin | 20.56% | ↓ 17.46% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.3B | ↓ 24.73% |
Net Income | 5.5B | ↑ 10.97% |
Net Profit Margin | 30.32% | ↑ 9.76% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 171.8B | ↑ 0.1% |
Total Liabilities | 100.1B | ↓ 10.41% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 159.4B | ↓ 7.2% |
Total Liabilities | 95.7B | ↓ 4.47% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 167.5B | ↑ 5.06% |
Total Liabilities | 104.0B | ↑ 8.76% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 154.2B | ↓ 7.92% |
Total Liabilities | 90.8B | ↓ 12.77% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 181.5B | ↑ 17.67% |
Total Liabilities | 104.0B | ↑ 14.61% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 197.2B | ↑ 8.67% |
Total Liabilities | 101.3B | ↓ 2.62% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 181.5B | ↑ 1.28% |
Total Liabilities | 104.0B | ↑ 0.77% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 183.8B | ↑ 1.3% |
Total Liabilities | 101.2B | ↓ 2.75% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 195.3B | ↑ 6.23% |
Total Liabilities | 107.8B | ↑ 6.59% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 195.4B | ↑ 0.03% |
Total Liabilities | 102.5B | ↓ 4.97% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 197.2B | ↑ 0.95% |
Total Liabilities | 101.3B | ↓ 1.14% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 16.5B | ↑ 3.58% |
Investing Cash Flow | -4.7B | ↓ 39.3% |
Financing Cash Flow | -13.0B | ↑ 46.12% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 15.8B | ↓ 3.9% |
Investing Cash Flow | 4.5B | ↓ 195.44% |
Financing Cash Flow | -20.4B | ↑ 56.82% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 12.6B | ↓ 20.47% |
Investing Cash Flow | -3.9B | ↓ 187.18% |
Financing Cash Flow | -8.5B | ↓ 58.49% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.4B | ↑ 14.42% |
Investing Cash Flow | -4.3B | ↑ 8.26% |
Financing Cash Flow | -9.6B | ↑ 13.72% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 32.6B | ↑ 126.2% |
Investing Cash Flow | -22.5B | ↑ 427.89% |
Financing Cash Flow | -9.8B | ↑ 1.73% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 29.3B | ↓ 10.17% |
Investing Cash Flow | -15.8B | ↓ 30.0% |
Financing Cash Flow | -14.8B | ↑ 51.12% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 5.9B | ↓ 45.39% |
Investing Cash Flow | -2.6B | ↓ 74.34% |
Financing Cash Flow | -3.4B | ↑ 204.36% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 6.5B | ↑ 10.6% |
Investing Cash Flow | 567.0M | ↓ 121.93% |
Financing Cash Flow | -6.6B | ↑ 96.3% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 8.2B | ↑ 24.9% |
Investing Cash Flow | -11.3B | ↓ 2095.24% |
Financing Cash Flow | 2.5B | ↓ 138.31% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 6.0B | ↓ 26.88% |
Investing Cash Flow | -627.0M | ↓ 94.46% |
Financing Cash Flow | -5.8B | ↓ 328.61% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 8.6B | ↑ 43.66% |
Investing Cash Flow | -15.8B | ↑ 2417.22% |
Financing Cash Flow | -5.0B | ↓ 12.95% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.2B | ↓ 85.88% |
Investing Cash Flow | 3.3B | ↓ 121.0% |
Financing Cash Flow | -2.8B | ↓ 44.75% |
Sell
Neutral
Buy
Pfizer Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Pfizer Inc. | -2.66% | -25.32% | -27.83% | 5.14% | 4.31% |
![]() Procter & Gamble Company, The | -7.97% | -4.42% | -2.21% | 21.94% | 94.07% |
![]() Johnson & Johnson | -6.36% | -13.61% | -12.76% | 4.24% | 26.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Pfizer Inc. | 7.5 | 7.5 | 1.17 | 3.35 | 0.32 | 0.12 | 0.04 | 17.89 |
![]() Procter & Gamble Company, The | 24.32 | 24.32 | 4.98 | 5.86 | 31.56 | 0.1 | 0.03 | 18.8 |
![]() Johnson & Johnson | 17.79 | 17.79 | 3.79 | 10.66 | 17.48 | 0.09 | 0.03 | 27.28 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Pfizer Inc. | Buy | $214.6B | 4.31% | 7.5 | 31.25% |
![]() Procter & Gamble Company, The | Buy | $337.5B | 94.07% | 24.32 | 17.69% |
![]() Johnson & Johnson | Hold | $401.2B | 26.72% | 17.79 | 13.22% |
Vanguard Group Inc
BlackRock Inc
State Street Corporation
Capital World Investors
Wellington Management Company LLP
Geode Capital Management, LLC
In the quarter ending March,2023. Pfizer Inc. has declared dividend of $0.41
Read More“Pfizer Inc., founded in 1849 by Charles Pfizer and Charles F. Erhart, is an American Biotechnology and Pharmaceutical giant. It is currently headquartered in New York City, United States with worldwide operations and distributions. To ensure that the medicinal and vaccine requirements of every patient and individual are met, Pfizer has been adopting a rigorous and scientific approach towards its supply chain. They now have a network of 58 manufacturing sites around the world under Pfizer Global Supply (PGS). To further expand its operations in the research and pharmaceutical sphere, it entered various merger and acquisitions deals with other players including Wyeth, Pharmacia, Warner-Lambert, Innopharma, etc. Its primary focus areas include internal medicine, rare diseases, vaccines, inflammation, immunology, oncology, and anti-infectives. They have major R&D platforms in the fields of gene therapy, precision medicine, biosimilars, medicinal sciences, and maternal immunizations. Pfizer Is traded under the ticker symbol of PFE. The financials of Pfizer are as follows: While Pfizer clocked a revenue of $41.908 billion for 2020, its net income amounted to $6985 million for the same period. Pfizer has made significant contributions in the fight against Covid-19 and has been successful in the early development of the Pfizer-BioNTech Vocid-19 vaccine. In 2020, Pfizer achieved the Top Employer Certification for the 5th year in the UK. Going by the revenue, Pfizer is the 4th largest pharmaceutical company globally and the 3rd largest in terms of market capitalization. It is currently traded in NYSE and other indices, including S&P 100, S&P 500, and Russell 1000 Index. Currently Pfizer Inc. has a market cap of $214.63 Billion. It has a P.E ratio of 7.39. The shares of Pfizer Inc. are trading at $38.02. ” .
Organization | Pfizer Inc. |
Employees | 83000 |
CEO | Dr. Albert Bourla D.V.M., DVM, Ph.D. |
Industry | Health Technology |